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Abstract
Objective
To study the trends of arrhythmia hospitalizations with cannabis use disorders (CUDs) in terms
of demographic characteristics and inpatient outcomes.
Methods
We used the nationwide inpatient sample (NIS) data during the post-legalization period (2010-
2014) and included 570,556 arrhythmia inpatients (age, 15-54 years), and 14,426 inpatients had
comorbid CUD (2.53%). We used the linear-by-linear association test and independent-sample
T-test for assessing the change in hospital outcomes in inpatients with CUD.
Results
Arrhythmia hospitalizations with CUD increased by 31% (2010-2014). This increasing trend was
seen in adults (45-54 years, P < 0.001) and was predominant in males (77.6%). Hypertension
(40.6%), hyperlipidemia (17.6%), and obesity (15%) were prevalent medical comorbidities with
variable trends over the five years. Among substance use disorders, tobacco (50.9%), and
alcohol (31.4%) were major comorbidities with a variable trend (P = 0.003 for each). There was a
71.4% increase in the inpatient mortality rate between 2010 (0.7%) and 2014 (1.2%). The mean
length of stay was three days, and the total hospitalization charges have been increasing (P <
0.001), averaging $35,812 per hospital admission.
Conclusion
Chronic cannabis use or abuse worsens hospitalization outcomes in arrhythmic patients, and
more clinical studies are needed to study the causal association between these conditions due
to the rising mortality risk.
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Introduction
Arrhythmia describes an irregular heartbeat - the heart may beat too rapidly (tachycardia), too
slowly (bradycardia), too early (premature contraction), or irregularly (flutter or fibrillation).
Any interruption to the electrical impulses that cause the heart to contract can result in
arrhythmia. Several factors can cause the heart to work incorrectly, including alcohol abuse,
diabetes, substance abuse, excessive coffee consumption, congestive heart failure,
hypertension, hyperthyroidism, mental stress, scarring of the heart due to a heart attack, and
smoking. A healthy person will hardly ever suffer from long-term arrhythmia unless they have
an external trigger, such as drug abuse or an electric shock. Most arrhythmias are non-fatal, but
some can predispose the individual to stroke or cardiac arrest.
Currently, cannabis is used by a large proportion of the world population. It is produced on a
large scale, and it is mainly used as an illicit substance by a large number of people across the
world. It is estimated that 182.5 million people all over the world are using cannabis, which is
about 3.8% of the total world population. Similarly, cannabis use is seen in the North American
population, with an estimated annual prevalence of 11.6%, the majority within the age group of
15 to 64 years [1]. Since the majority of the people around the world, especially youth, use
cannabis for recreational purposes, the trend of which is increasing globally, many people have
led movements to decriminalize cannabis in different parts of the world. Recently, cannabis has
been approved for use clinically for several medical conditions in various parts of the world. In
the United States (US), a total of 25 states and the District of Columbia have allowed the use of
cannabis for medical purposes [2].
Cannabis has arrhythmogenic properties [3-6]. Cannabis causes rapid development of tolerance
to its effects with repeated exposures within a short period over one to two days. Chronic
marijuana use causes a decrease in sympathetic activity and an increase in parasympathetic
activity. These changes are reflected in our body by a decrease in heart rate (HR), increase in
blood volume, absence of orthostatic hypotension, and decrease in circulatory response to
exercise [6].
Several studies have demonstrated the arrhythmogenic properties of cannabis. A study on
Norwegian apprehended drivers demonstrated that a higher mean pulse rate is seen in drivers
who are tested positive for tetrahydrocannabinol (THC, an active ingredient of cannabis) as
compared to drivers who are tested negative for THC. It also demonstrated that the rate of
increase in HR was independent of the THC concentration in the blood [7]. A study on young
people demonstrated that cannabis use causes atrial fibrillation in young people without any
risk factors for atrial fibrillation in them [4,8]. In a systematic review of six case reports,
Korantzopoulos et al. [4] hypothesized that cannabis use causes adrenergic stimulation and a
decrease in the duration of the action potential. It causes changes in the electrophysiological
properties of the myocardium, which favors automaticity and micro re-entry. Cannabis has a
detrimental effect on coronary microcirculation and it causes atrial ischemia. Based on this,
they concluded that cannabis smoking causes atrial fibrillation [4]. There are few case reports
on cannabis use and ventricular tachycardia/fibrillation that may be due to excessive
catecholamine release [9-11]. Some case reports demonstrated that excessive cannabis
consumption causes a shortening of action potential and an increase in the vagal tone, which
leads to Brugada-like ST-segment abnormalities [12-14].
The objective of this study is to study the trends of hospitalizations for arrhythmias with
cannabis use disorder (CUD) in terms of demographic characteristics and inpatient outcomes,
including the severity of illness, length of stay (LOS), and total charges during hospitalization.
Materials And Methods
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Data source
We performed a retrospective analysis of the nationwide inpatient sample (NIS) data from
January 2010 to December 2014 from the healthcare cost and utilization project (HCUP) [15].
The NIS provides discharge data from 4,400 hospitals across 45 states in the US, and when
discharge weights are applied, the analysis result is a weighted estimate of nationally-
representative total hospitalizations [15]. Diagnostic information in the NIS is detected using
the international classification of diseases, ninth edition (ICD-9) codes and clinical
classification software (CCS) codes [16].
Inclusion criteria and outcome variables
We included patients (age 15 to 54 years) with a primary discharge diagnosis of cardiac
arrhythmia using the ICD-9 codes 427.0-427.2, 427.31, 427.32, 427.60, 427.61, 427.69, 427.81,
427.89, 427.9, 785.0, or 785.1) and a secondary discharge diagnosis of CUD using the ICD-9
codes 304.30, 304.31, 304.32, 305.20, 305.21, or 305.22 [17].
Demographic variables studied included age group (15-24, 25-34, 35-44, 45-54), gender (male
or female), and race (Caucasian, African American, Hispanic, or other) [18]. The existing risk
factors for cardiac arrhythmia were based on the past literature and identified using ICD-9
diagnosis codes and CCS codes.
We evaluated the differences in inpatient outcomes in the study population, and the outcome
variables comprised the severity of illness (loss of functions measured as minor, moderate, and
major) and in-hospital mortality (number of deaths during hospitalization) [18]. In the NIS,
LOS is calculated as the total number of nights the patient was hospitalized for arrhythmia
management and the total charges during hospitalization do not include professional fees and
other non-covered charges [18].
Statistical analysis
We used the linear-by-linear association test for assessing the differences in demographics,
comorbidities, and inpatient outcomes and the independent sample T-test for evaluating the
changes seen in LOS and total charges over the study period from 2010 to 2014. A P-value
less than 0.05 was used to determine the statistical significance and the analysis was conducted
on the statistical package for the social sciences (SPSS) version 25 (IBM Corporation, Armonk,
NY, US).
Ethical approval
Individual identifiers [18] were used to protect the patient's identity and other clinical
information. The use of NIS under the HCUP does not require approval from the institutional
review board, as the NIS is a publicly available de-identified database [15].
Results
We analyzed 570,556 patients with a principal discharge diagnosis of arrhythmias from 2010 to
2014, from which 14,426 inpatients had comorbid CUD (2.53%). Arrhythmia inpatients with
CUD were mostly males (77.6%) and adults (age 45 to 54 years, 43.4%). About half of them were
Caucasians (51.2%) followed by African Americans (34.1%), Hispanics (9.8%), and other races or
ethnicities (4.8%).
There was an increasing trend in arrhythmia hospitalizations with comorbid CUD from 2,536
(in 2010) to 3,325 (in 2014), representing a 31% increase over five years. There are variable
trends in CUD with arrhythmia over the years from 2010 to 2014 in the age groups 15-24, 25-34,
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and 35-44 (P < 0.001). There is a statistically significant increasing trend seen in the age group
45-54 (P < 0.001). Arrhythmia was predominant in male cannabis users (77.6%), but there was a
variable trend seen from 2010 to 2014. Differences between races showed statistically non-
significant and variable trends (P = 0.474) among Caucasians (51.2%), African Americans
(34.1%), Hispanics (9.8%), and other races or ethnicities (4.8%).
Hypertension (40.6%), hyperlipidemia (17.6%), and obesity (15%) were the most common
medical comorbidities found in arrhythmia inpatients with CUD. There are variable trends in
arrhythmia with CUD patients with comorbid diabetes, hypertension, obesity, elevated
cholesterol, and lipids over the five-year study period. Among substance use disorders, tobacco
(50.9%) and alcohol (31.4%) were significant comorbidities in these inpatients. Variable trends
are seen with comorbid alcohol and tobacco use disorder in arrhythmia with CUD patients with
statistical significance (P = 0.003), as shown in Table 1.
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Variable 2010 2011 2012 2013 2014 Total Pvalue
Number of arrhythmia inpatients 122592 122749 116610 108050 100555 570556 -
Number of arrhythmia inpatients with cannabis
use disorder 2536 2885 2875 2805 3325 14426 -
Prevalence 2.0 2.3 2.4 2.6 3.3 2.5  
Age at admission, in %
15 – 24 years 12.6 16.0 12.0 14.6 12.9 13.6
<0.001
25 – 34 years 25.0 22.3 21.0 23.4 20.0 22.2
35 – 44 years 20.7 20.7 22.8 18.0 21.5 20.8
45 – 54 years 41.7 41.0 44.2 44.0 45.6 43.4
Sex, in %
Male 76.3 77.3 75.0 78.4 80.6 77.6
<0.001
Female 23.7 22.7 25.0 21.6 19.4 22.4
Race, in %
Caucasian 47.2 54.2 51.1 51.5 51.6 51.2
0.474
African American 38.3 31.9 33.2 31.8 35.6 34.1
Hispanic 9.6 9.5 10.7 11.4 8.2 9.8
Other 4.8 4.3 5.1 5.3 4.6 4.8
Comorbid risk factors, in %
Diabetes 9.8 10.0 9.2 10.7 12.2 10.5 0.001
Hypertension 34.8 42.8 40.2 39.2 44.7 40.6 <0.001
Obesity 9.1 16.4 17.6 14.4 16.5 15.0 <0.001
Elevated cholesterol and lipids 14.8 18.1 20.0 17.5 17.3 17.6 0.104
Alcohol use disorder 32.3 34.7 28.3 32.3 29.6 31.4 0.003
Tobacco use disorder 50.6 51.4 44.3 55.1 52.9 50.9 0.003
TABLE 1: Demographic trends of arrhythmia inpatients with cannabis use disorder
Majority of the inpatients with CUD were admitted for arrhythmia on a non-elective basis
(95.8%). There are variable trends in arrhythmic inpatients with CUD developing minor,
moderate, and major severity of illness over the years from 2010 to 2014 with statistical
significance (P < 0.001). The mean number of chronic conditions is also variable with statistical
2019 Jaladi et al. Cureus 11(9): e5607. DOI 10.7759/cureus.5607 5 of 10
significance (P < 0.001). Arrhythmia inpatients with CUD had a variable trend (P < 0.001) in
inpatient mortality, but there is 71.4% increase in the inpatient mortality rate between 2010
(0.7%) and 2014 (1.2%). Trends in inpatient outcomes in arrhythmia hospitalizations with CUD
are shown in Table 2. 
Variable 2010 2011 2012 2013 2014 Total P value
Admission type, in %
Non-elective 95.0 95.7 96.0 97.0 95.3 95.8
0.005
Elective 5.0 4.3 4.0 3.0 4.7 4.2
Severity of illness, in %
Minor 34.6 32.7 35.7 38.3 30.5 34.2
<0.001Moderate 40.1 38.8 44.5 39.8 42.7 41.2
Major 25.4 28.6 19.8 21.9 26.8 24.6
Mean number of chronic conditions
(SD)
5.8
(2.57)
6.2
(2.77)
6.3
(2.82)
6.3
(2.84)
6.7
(2.91)
6.3
(2.81) <0.001
In-hospital mortality, in %
Inpatient deaths 0.7 0.7 1.4 0.2 1.2 0.9 <0.001
Other outcomes
Mean length of stay (SD), in days 2.9(2.89)
2.8
(3.07)
2.8
(3.10)
3.2
(6.03)
3.2
(3.27)
3.0
(3.85) <0.001
Mean total charges (SD), in $ 33561.94 31614.48 31192.38 37891.46 43470.28 35812.28 <0.001
TABLE 2: Inpatient outcome trends of arrhythmia inpatients with cannabis use
disorder
SD: standard deviation
The mean LOS was three days, and it remains more or less around three days over the study
period with statistical significance (P < 0.001), whereas total hospitalization charges have been
increasing significantly (P < 0.001), averaging $35,812 per hospital admission, as shown in
Figure 1.
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FIGURE 1: Trends in inpatient mean length of stay and total
charges, 2010-2014
Discussion
This study describes the trend examination of arrhythmia hospitalizations and comorbid CUD
using the US population-based inpatient data during the post-legalization period (2010 to
2014). Our study findings are supporting existing literature about cannabis abuse and
dependence and its impact on vascular function and arrhythmia [3-6,19-20].
Cannabis has arrhythmogenic properties. Cannabis smoking causes reflex tachycardia due to
cannabis-induced vasodilation [3-4]. It causes a 20% to 100% increase in HR. It also causes a
slight increase in supine blood pressure. This increase in HR lasts for about two to three hours.
Cannabis causes postural hypotension associated with dizziness and fainting when consumed
in higher doses [5-6].
Our study showed a significant increase in arrhythmia hospitalizations with comorbid CUD by
31% during the post-legalization period that brings an important public health concern. CUD
may be an associated risk factor for hospitalization due to its arrhythmogenic properties. These
patients have various comorbid conditions like diabetes, hypertension, obesity, elevated
cholesterol and lipids, and alcohol and tobacco abuse. These risk factors also play a significant
role in the development of arrhythmia in patients with cannabis abuse or dependence [4,7-8].
These comorbid risk factors may have synergistic effects with cannabis and potentially increase
the chances of arrhythmia hospitalization.
We found that a higher proportion of arrhythmia hospitalizations with CUD were in adults aged
45 to 54 years, which may be due to an increase in comorbid conditions at an older age [21].
There are few case reports on chronic cannabis use and ventricular tachycardia/fibrillation that
may be due to excessive catecholamine release [10-11]. It is speculated that excessive
catecholamine release in cannabis users could be responsible for the arrhythmia [11]. In our
study, 52.9% arrhythmia inpatients with CUD have comorbid tobacco abuse or dependence,
which indicates an important problem of tobacco in cannabis users that may increase the
chances of arrhythmia hospitalizations [22].
The study highlights the increase in arrhythmia hospitalizations, total inpatient charges, and
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mortality in patients with comorbid CUD. This is mainly reflected by several findings in our
study, including increase in the mean length of stay (three days), average hospitalization total
charges of $35,812, and 71.4% increase in in-hospital mortality during the management of
arrhythmia [20,23]. The increase in hospitalization costs is due to an increase in the overall
severity of illness by 5.5% [20] and a number of chronic conditions by 15.52% [21,24-25].
There are some limitations to our study. As per our knowledge, this is one of the pioneer
studies; we did not have enough literature to support our results adequately. Our study
nevertheless utilizes the NIS dataset and lays the basis for these results, which will have
substantial consequences for future studies. The second limitation was that the readmission
status for the participants could not be looked upon, and this is due to the nature of the
database. However, since this database is a robust population-based register with a high
generalisability, it outweighs the significance of these results in comparison to limitations for
this study. This research nevertheless possesses some strengths. First, in the form of
generalization of outcomes, our research shows strong internal validity. Secondly, this is the
first study that evaluates the patterns and effects of CUD on arrhythmia hospitalization and its
impact on inpatient outcomes. The study findings indicate that healthcare expenses are
increasing inadvertently, primarily due to the use of cannabis and to avoidable risk factors. The
ultimate strength of the study is how the study eliminates a reporting bias by using the NIS
dataset, and its distinctive feature is that information is coded separately from the physician.
Conclusions
There is a decreasing trend in the number of arrhythmia cases in inpatient US hospitalizations,
but there is an increase in the number of inpatient hospitalizations with arrhythmia having
CUD as per our study. A statistically significant rising trend of arrhythmia hospitalization with
CUD is seen in adults (45 to 54 years), males, and Caucasians. Cardiometabolic comorbidities,
including diabetes, hypertension, and obesity, had an increasing linear trend in these
inpatients. Hence, there was a spike seen in the severity of illness and the number of chronic
conditions, which may have indirectly attributed to the increasing hospitalization costs for
arrhythmia management in cannabis users. Despite all these measures, in-hospital mortality
rose by 71.4% during the post-legalization period. The outcomes in arrhythmic patients with
CUD are presumably worse due to chronic cannabis abuse. More clinical studies are required to
demonstrate a causal association between episodic cannabis use and arrhythmia. Since medical
cannabis laws are passed in the US, large-scale epidemiological studies are also needed to
assess the potential risks in cannabis users due to an increase in the use of cannabis for
therapeutic purposes.
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